Thymosin Beta-4 dosing & administration
The body's natural healing peptide that accelerates tissue repair and reduces inflammation
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team
Dosing
How much do I take?
Subcutaneous injection: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
2-5 mg (community injectable practice for 'TB-500')
Frequency
Once or twice weekly
Duration
4-6 week loading phase, then weekly maintenance
Documented community/research-practice injectable dosing for tissue repair; thymosin beta-4 has ~100% bioavailability by the subcutaneous route [1]. Not an FDA-approved use.
Timing
Best time to take
Morning or evening (flexible)
With food?
Not affected by food intake
If stacking
Best administered on different days than other injectable peptides to minimize injection site stress
Adjusting your dose
Increase if
- Healing is slower than expected after 3-4 weeks
- Inflammation remains high despite initial treatment
- Underlying injury is more severe than initially assessed
Decrease if
- Injection site reactions become bothersome
- Excessive bruising or swelling develops
- Systemic sensitivity symptoms appear
Signs of right dose
- Visible improvement in wound appearance by week 2-3
- Reduced pain and inflammation
- Improved range of motion around injured area
- Faster scar maturation
Administration
How do I use it?
Reconstitution
What you need
Example
For a 5 mg vial: Add 5 mL bacteriostatic water = 1 mg/mL solution. Each 0.1 mL = 0.1 mg (100 mcg)
Desired dose (mg) × mL per mg concentration = volume to inject. Example: 2 mg dose from 1 mg/mL solution = 2 mL
Injection
Route
Subcutaneous
Best sites
Technique
- 01Clean skin with alcohol swab and let dry
- 02Pinch skin gently to create subcutaneous fold
- 03Insert needle at 45-90 degree angle
- 04Inject slowly over 2-3 seconds
- 05Withdraw needle and apply light pressure
- 06Rotate injection sites to prevent lipohypertrophy
Storage
Before reconstitution
Keep in original vial at 2-8°C. Protect from light and freezing. Stable for 36+ months when properly stored
After reconstitution
Store at 2-8°C in refrigerator. Do not freeze reconstituted solution
Signs of degradation — discard the vial
Sample daily schedule
Monday morning
2-5 mg injection
Site: Lower abdomen or outer thigh
First dose of the week (loading phase)
Thursday morning
2-5 mg injection
Site: Opposite thigh or upper arm
Second dose of the week (loading phase, then transition to maintenance)
Weekly (maintenance)
2 mg injection
Site: Rotate between abdomen, thighs, and arms
After 4-6 week loading phase, reduce to once weekly for maintenance
Safety
Is it safe?
Safety profile
Thymosin Beta-4 is a naturally occurring peptide found in all cells and body fluids in the human body. Clinical trials have demonstrated excellent safety even at very high doses. IV studies showed doses up to 1260 mg were well tolerated with no serious adverse events.
Multiple Phase 1, Phase 2, and Phase 3 clinical trials completed. Phase 1 study showed dose-proportional pharmacokinetics with increasing half-life at higher doses, indicating predictable and safe dosing.
Common side effects
Experienced by some users
Injection site redness
Mild redness at the site of injection, usually resolves within hours to a few days
Management: Ice pack immediately after injection, rotate injection sites, use proper sterile technique
Injection site swelling
Mild swelling or puffiness at injection site, typically mild and temporary
Management: Ice compress for 10-15 minutes after injection, elevate area if applicable
Less common
- Temporary mild headache
- Mild bruising at injection site
- Transient fatigue
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe allergic reaction or anaphylaxis
- Persistent injection site infection
- Significant systemic adverse effects
- Pregnancy is confirmed
- No improvement in healing after 12 weeks (reassess approach)
- Active systemic infection develops without antibiotic coverage
This is general educational information. Always consult with a healthcare provider before starting, stopping, or modifying any peptide therapy. Do not self-diagnose or treat serious medical conditions.
Interactions
With other peptides
With medications
With supplements
Published research
What the studies show
Sosne G, et al. · 2016
This study investigated the properties and effects of Thymosin Beta-4, contributing to our understanding of its mechanism of action and potential therapeutic applications.
Metcalfe JC, et al. · 2015
This study investigated the properties and effects of Thymosin Beta-4, contributing to our understanding of its mechanism of action and potential therapeutic applications.
Philp D, et al. · 2017
This study investigated the properties and effects of Thymosin Beta-4, contributing to our understanding of its mechanism of action and potential therapeutic applications.
Brown DM, et al. · 2018
This study investigated the properties and effects of Thymosin Beta-4, contributing to our understanding of its mechanism of action and potential therapeutic applications.
Sosne G, Ousler GW, et al. · 2022
RegeneRx Biopharmaceuticals (NCT01311518) · 2011
Head to head
Thymosin Beta-4 compared
Want the full picture?
The complete Thymosin Beta-4 research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.